Semaglutide News and Research

Latest Semaglutide News and Research

High discontinuation rates of GLP-1 agonists found among patients with obesity

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting treatment effectiveness.

4 Feb 2025

Prescription trends for obesity medications surge, tied to growing interest in GLP-1 drugs

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest influences prescription trends.

3 Feb 2025

Gut-derived sugars: A potential game-changer for weight management and diabetes

Gut bacteria-produced exopolysaccharides (EPS) help regulate metabolism by modulating gut microbiota, promoting SCFA production, and improving glucose homeostasis. S. salivarius, a key EPS producer, shows potential for obesity and diabetes intervention.

30 Jan 2025

Revolutionizing diabetes care with innovative targets and therapeutic options

A thorough examination of modern drugs that target particular receptors and metabolic pathways for glucose and fat metabolism is presented. Recent research has revealed innovative targets and therapeutic options.

30 Jan 2025

Weekly diabetes injection could replace daily shots for lipodystrophy patients

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone shots for people with a rare genetic form of lipodystrophy that leaves patients with almost zero fat tissue, according to a study in The New England Journal of Medicine.

29 Jan 2025

Boosting BCL6 may counteract muscle loss from GLP-1 medications

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal.

23 Jan 2025

What causes behavioral side effects in popular weight loss drugs?

The study of GLP1R variants shows associations with cardiometabolic traits and behavioral changes, highlighting indirect effects of GLP1RA on mental health.

23 Jan 2025

Why do people with obesity, but without diabetes, start taking semaglutide?

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing significant insurance coverage disparities.

22 Jan 2025

GLP1RA medications linked to behavioral side effects in type 2 diabetes and obesity

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents-have been linked with behavioral side effects.

22 Jan 2025

Childhood obesity treatment reduces long-term health risks but not depression

When children with obesity undergo weight-loss treatment, the effects have repercussions later in life and the risk of serious health problems and premature death is lower as they reach young adulthood.

21 Jan 2025

Benefits and risks of popular weight-loss drugs revealed

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes, heart disease or obesity.

20 Jan 2025

Researchers create an atlas of health associations for GLP-1 receptor agonists

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for gastrointestinal and musculoskeletal issues.

20 Jan 2025

Intestinal bacterium found to reduce sugar intake in diabetic mice and humans

Excessive sugar consumption is linked to several non-communicable diseases, including obesity, cardiovascular disease, metabolic syndrome, and type 2 diabetes.

17 Jan 2025

AstraZeneca's Pioneering Research in Heart Failure and ATTR-CM

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing critical needs in cardiovascular health.

16 Jan 2025

Semaglutide improves glycemic control with automated insulin delivery

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin requirements and aiding weight management.

15 Jan 2025

Unveiling the hidden benefit of bariatric surgery

Welcoming a newborn is something many couples dream of doing, but it can get complicated when conceiving becomes a roadblock. Infertility affects one in six people, but obesity can also be a problem. When diet and exercise aren't enough to lose weight, bariatric surgery can become an option. Yet a new national survey by Orlando Health finds that 56% of Americans do not know that bariatric surgery is an effective way to improve fertility.

14 Jan 2025

Gut bacterium associated with reduced dietary sugar intake

This study links Ffar4, gut microbiota, and sugar preference, highlighting potential strategies for managing diabetes and obesity through dietary interventions.

13 Jan 2025

Statistical model analyzes the cost-effectiveness of semaglutide for non-diabetic obese individuals

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

9 Jan 2025

GLP-1 drugs linked to fewer post-surgical complications in diabetic patients

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower rates of hospital readmission, wound re-opening and hematoma after surgery, according to a large study led by investigators at Weill Cornell Medicine, Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.

6 Jan 2025

Do GLP-1 receptor agonists increase the risk of suicide in patients?

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal behaviors in high-risk populations.

6 Jan 2025